Prediction of Cardiotoxicity Using Serum N-Terminal Pro-B-Type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab.
Phase of Trial: Phase IV
Latest Information Update: 27 Apr 2015
At a glance
- Drugs Trastuzumab (Primary) ; Anthracyclines
- Indications Early breast cancer
- Focus Adverse reactions; Biomarker
- Acronyms CATS
- 15 Apr 2013 Planned end date changed from 1 Feb 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 15 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Jul 2011 Planned End Date changed from 1 Feb 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.